whatpeptidestostack
← Compound library
CJC-1295
A long-acting GHRH analogue studied for growth-hormone release. Two early human trials measured hormone levels; no human study here reports a functional outcome.
The basics
| Human protocol on record | 4 figures |
|---|---|
| Animal or laboratory figures | 2 |
| Published records retrieved | 16 |
| Registered trials | 2 |
| Certificate of analysis | Published by the partner |
| Regulatory status | Research-grade material, no approved human use |
1. The protocol on record
Hard disclaimer. Figures below are transcribed from a published study or an approved label exactly as the source states them. They record what researchers administered in a trial population, not instructions for any person, and none of it is adjusted to you. Most compounds here have no approved human use. Do not act on any of it without a licensed prescriber who knows your history.
Amounts and schedules, human record
| Phase or model | Amount | Frequency | Timing | Route | Duration | Source |
|---|---|---|---|---|---|---|
| Randomized, placebo-controlled, double-blind ascending single-dose study in healthy adults (first of two trials) | Four ascending single doses; the abstract names 30 or 60 microg/kg as particularly well tolerated and does not enumerate the four doses | single dose | not stated | subcutaneous | 28-day trial duration | source |
| Randomized, placebo-controlled, double-blind multiple-dose study in healthy adults (second of two trials) | not stated | two or three weekly or biweekly doses | not stated | subcutaneous | 49-day trial duration; mean IGF-I levels remained above baseline for up to 28 days after multiple doses | source |
| Serum protein biomarker study in 11 healthy young adult men | not stated | single injection | not stated | not stated | single injection; serum sampled before and one week after injection | source |
| Phase 2 trial in HIV patients with visceral obesity (terminated) | not stated | not stated | not stated | not stated | not stated | source |
Animal and laboratory models (not human figures)
| Phase or model | Amount | Frequency | Timing | Route | Duration | Source |
|---|---|---|---|---|---|---|
| Murine model of glucocorticoid-induced muscle loss, CJC-1295 combined with ipamorelin | not stated | not stated | not stated | not stated | not stated | source |
| Administration in thoroughbred race horses, cited to confirm an anti-doping detection assay | not stated | not stated | not stated | not stated | not stated | source |
Half-life and why the schedule looks like that
- The estimated half-life of CJC-1295 was 5.8 to 8.1 days after subcutaneous injection in healthy adults (PMID 16352683). - After a single injection, mean plasma GH concentrations rose 2- to 10-fold for 6 days or more, and mean plasma IGF-I concentrations rose 1.5- to 3-fold for 9 to 11 days. After multiple doses, mean IGF-I levels remained above baseline for up to 28 days (PMID 16352683). - A separate record attributes the prolonged activity to a maleimido group that covalently binds plasma proteins such as serum albumin; the resulting conjugates have a much greater half-life than the unconjugated peptide and stimulated GH production for more than six days in humans after a single administr
Handling and storage
- Lyophilised storage: Not stated in the cited record. - Storage after reconstitution: Not stated in the cited record. - Temperature: Not stated in the cited record. - Light: Not stated in the cited record. - Stability duration: Not stated in the cited record. The only stability-related statements are in vivo: an estimated half-life of 5.8 to 8.1 days after subcutaneous injection (PMID 16352683) attributed to covalent binding of the peptide to plasma proteins (PMID 30938069).
These figures summarise what published research and approved labels describe. They are educational, not a recommendation or a personal protocol. Any dose, schedule, or decision to use a compound belongs with a licensed prescriber.
Open the interactive builder for reconstitution maths and a calendar →
2. Safety and harm reduction
Reported adverse effects
No adverse effects are reported in the cited record for CJC-1295. That is an absence of published reporting, not evidence of safety.
Cautions stated in the literature
- CJC-1295 is an unapproved compound; reviews state that unapproved peptides circulate in a "gray market" outside regulatory oversight, with products often mislabeled or contaminated, and with potential for serious harm (PMID 41966639, PMID 41880199, PMID 42160466).
- Reviews state that rigorous human safety data are scarce, that non-approved peptides lack long-term safety data and systematic validation, and that further studies are needed before most new peptides can be used safely in humans (PMID 41966639, PMID 42021992, PMID 42123471).
- A review of peptide use in sport states that emerging data highlight potential risks including cardiovascular strain, insulin resistance, dyslipidemia, and psychiatric instability, and notes that most published studies examine controlled dosing regimens, not the supraphysiological or combined protocols common in bodybuilding (PMID 41880199).
- A study of female use documented concerns about gender variations in growth hormone pulses affecting estimation of dosage, cycling, and long-term consequences, and referred to related adverse health consequences of self-medicating use (PMID 26771670).
- GHRH and its synthetic analogs, including CJC-1295, are prohibited by the World Anti-Doping Agency; multiple records describe anti-doping detection methods for it in human and equine samples (PMID 34665524, PMID 30938069, PMID 30489688, PMID 38716080).
- The phase 2 trial of CJC-1295 in HIV patients with visceral obesity is recorded as terminated; the record does not state a reason (NCT00267527).
- Reviews classify growth hormone axis secretagogues including CJC-1295 as investigational, with uncertain safety profiles and product quality concerns, and state that clinical use should be confined to approved agents and rigorously designed research protocols (PMID 42160466).
Stop and get help
- A severe or worsening reaction of any kind after administration.
- Signs of an allergic reaction, such as hives, swelling of the face or throat, wheezing, or difficulty breathing.
- Signs of injection-site infection, such as spreading redness, warmth, swelling, pain, pus, or fever.
- Anything unexpected and persistent, whether or not it appears on this page.
- In any of these circumstances, the general harm-reduction line is to stop and contact a licensed clinician.
Pairings
Mentioned together
BPC-157 and CJC-1295
Named together in the same review articles, never tested together. This page says that plainly and shows why researchers list them side by side.
Open the pairing brief →Mentioned together
CJC-1295 and GHK-Cu
Named together in the same review articles, never tested together. This page says that plainly and shows why researchers list them side by side.
Open the pairing brief →Co-administered
CJC-1295 and Ipamorelin
A growth-hormone secretagogue pairing. One murine study has given both together; the human evidence is not there yet.
Open the pairing brief →Mentioned together
CJC-1295 and TB-500
Named together in the same review articles, never tested together. This page says that plainly and shows why researchers list them side by side.
Open the pairing brief →CJC-1295 at Peptara Labs
Open the CJC-1295 pageRead the third-party certificate of analysis before anything else. Research-grade material, research use only.